Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 565

Next Previous
Drug Profile

MEDI 565

Alternative Names: AMG-211; CEA BiTE mAb; MEDI-565; MT-111

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; MedImmune; University Medical Center Groningen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 05 Feb 2019 CTP push274228: kdm updated, HE created, not reviewed the profile
  • 25 Jan 2019 University Medical Center Groningen and Amgen discontinued a phase I/II PET imaging trial for Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Netherlands (IV), prior to January 2019 (EudraCT2015-004370-14)
  • 19 Oct 2018 Safety, pharmacokinetics and immunogenecity data from a phase I study in Gastrointestinal cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top